Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1661-1680 of 2,251 trials

Almagate for Heartburn in Pregnant Women

We are studying the safety of almagate for treating heartburn and reflux in pregnant women. The trial also examines how this treatment affects the health of the fetus and newborn.

Heartburn and Reflux>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics

Soft Tissue Sarcoma: Doxorubicin Chemotherapy Study

We are investigating whether adding doxorubicin-based chemotherapy helps patients with high-risk localized soft tissue sarcoma live longer without metastasis. This study compares it to standard treatment to assess safety and effectiveness.

Soft Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

CIDP: NVG-2089 Treatment Study

We are evaluating the safety and effectiveness of NVG-2089 for individuals with Chronic Inflammatory Demyelinating Polyneuropathy. This study aims to find out if it can help improve symptoms and overall health.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Staphylococcus Aureus Bacteremia: Shorter Antibiotic Treatment

We are studying whether 4 weeks of antibiotic treatment is as effective as 6 weeks for patients with complicated Staphylococcus aureus bacteremia who have improved after initial therapy.

Staphylococcus aureus Bacteremia6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

HIV-1 Control: Genetic and Immune Response Study

We are studying early-treated HIV-1 patients who stopped their antiretroviral therapy to find out if specific genetic and immune markers can predict their ability to control the virus. This research may help improve future treatment strategies.

HIV Positive During Acute Phase>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Gastrointestinal Stromal Tumor: Adjuvant Imatinib Study

We are studying whether adjuvant Imatinib can help prevent cancer recurrence in patients with intermediate-risk gastrointestinal stromal tumors. This trial compares its effects on survival and quality of life against standard treatments.

Gastrointestinal Stromal Tumor>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Ovarian Cancer: Tinzaparin and Biomarkers

We are studying how tinzaparin affects cancer marker levels in patients with advanced ovarian cancer receiving chemotherapy. This trial also looks at the drug's safety and its impact on immune and blood factors.

Epithelial Ovarian Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Artificial Cornea for Severe Corneal Ulcers

We are studying a new human-made cornea for patients with advanced corneal ulcers that don't improve with standard treatments. The trial aims to assess its safety and effectiveness in these challenging cases.

Corneal Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Decompensated Cirrhosis: New Human Albumin Solution

We are studying a new human albumin solution to see if it is safer and more effective than the standard treatment for patients with decompensated cirrhosis. This research aims to improve clinical outcomes for those needing long-term albumin therapy.

Decompensated Cirrhosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyInternal Medicine

OCTAPLEX for Major Bleeding in Patients on Blood Thinners

We are studying whether a higher dose of OCTAPLEX can effectively stop major bleeding in patients taking direct oral anticoagulants. The trial also looks at the safety of this treatment during emergencies.

Coagulation DisorderAcute Major Bleeding with DOAC Therapy≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHematology

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Emicizumab Dosing in Congenital Hemophilia A Patients

We are studying whether personalized dosing of emicizumab can effectively prevent bleeding in patients with congenital hemophilia A compared to standard dosing. This trial also examines the impact on quality of life and treatment costs.

Hemophilia A1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Gout Treatment: Immediate vs. Delayed Febuxostat

We are studying whether starting febuxostat right after a gout attack helps reduce the number of gout days compared to starting it six weeks later. This trial is for individuals experiencing acute gout attacks.

Gout>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyRheumatology